Resumen
Pancreatic neuroendocrine neoplasms (PNENs) are a type of pancreatic tumor. Everolimus is an oral inhibitor of the mammalian target of rapamycin (mTOR). Although PNENs respond well to systematic treatment, including everolimus, the treatment options are often exhausted in clinical practice with the progression of the tumor. Recently, the efficacy of molecular targeted drugs, including mTOR inhibitors, has been assessed in rechallenge experiments. The efficacy and safety of rechallenge with everolimus in PNENs remains unclear. This study retrospectively evaluated the treatment outcomes of patients who received everolimus rechallenge. Everolimus rechallenge may be a drug treatment option for those with advanced PNEN for whom no other drug treatment option is available.